glp-1 for crohn's Frontiers Relevance of Glucagon-Like Peptide 1

Author Contributions Writingoriginal draft preparation, H.P

The parallel is not exact, but it provides a plausible biological explanation for why some patients experience reduced sexual desire on GLP-1 therapy

In STEP-1 (Wilding et al., NEJM 2021), 68 weeks of once-weekly 2.4 mg semaglutide plus lifestyle intervention produced a mean body-weight reduction of about 15%, versus about 2.4% with placebo a large, clinically meaningful, well-replicated effect

Macleod, investigadores de la Universidad de Toronto, lograron aislar y purificar con xito la insulina, marcando un hito en la historia de la medicina

Nausea was found to be the most frequent side effect, followed by vomiting, injection site issues, constipation, pancreatitis, and gastroparesis